Introduction
Heart disease represents the predominant cause of death in b-thalassemia major (TM), 1 with cardiac iron by T2* cardiovascular magnetic resonance (CMR) being the strongest predictor. 2 Myocardial iron overload (MIO) can cause a toxic dilated cardiomyopathy that can be reversed if aggressive chelation is initiated early. 3, 4 However, clinical symptoms occur late in the disease process and mortality remains high if patients cannot comply with years of intensified therapy. 5 Although iron could be removed by chelation treatment, the induced heart damage could be not totally reversible. Moreover, heart disease in the ageing thalassemia population can also result from other causes: 6, 7 chronic anaemia, myocarditis, 8 particularly in areas at high prevalence of hepatitis C virus (HCV) infection, 9, 10 endocrine abnormalities, pulmonary hypertension, nutritional deficiencies, and genetic factors. 9, 11 T2* CMR with a single measurement in the mid-ventricular septum 12 or with a multislice approach 13 has been validated as a reproducible 14 quantitative method for MIO assessment. 15 By a multislice segmental approach it is possible to detach different patterns of iron distribution correlated with clinical endpoints. 16 Moreover, CMR provides the opportunity to quantify bi-atrial and biventricular function parameters with excellent reproducibility. 3, 7 Late gadolinium enhancement (LGE) CMR is a unique non-invasive technique validated to detect necrosis/fibrosis. 9, [17] [18] [19] Thus, CMR provides a unique means to characterize the complex thalassemia cardiomyopathy thank to its multiparametric potential.
No prospective data are available in literature about the relationship between the mutiparametric CMR findings (heart function and myocardial fibrosis, beyond MIO) and prediction of cardiac events.
So, we prospectively reassessed the predictive value of CMR for heart failure (HF) and arrhythmias using a multiparametric approach in TM.
Methods Patients
We included 537 TM patients. The study complied with the Declaration of Helsinki and was approved by the institutional ethics committee. All patients provided informed consent.
Patients performed their first MR scan between June 2004 and October 2008 within the Myocardial Iron Overload in Thalassemia (MIOT) network. 14, 20 By protocol, patients underwent follow-up MR examinations every 18 ± 3 months. All centres are linked by a shared database, 20 where clinical data are recorded from birth and updated at every MR. Clinical follow-up continued until June 2012. Each haematologist completed a case report form detailing patient outcomes between the last MR and June 2012.
Magnetic resonance
MR exams were performed using a 1.5T scanner (GE, Milwaukee, USA). An eight-element cardiac phased-array receiver surface coil with breathholding in end-expiration and ECG-gating were used.
For iron overload assessment, T2* gradient-echo multiecho sequences were acquired. For the heart a multislice approach was used: basal, medium, and apical slices were acquired. 13, 21 A mid-hepatic slice was obtained. 22 T2* images analysis was performed using a custom-written, previously validated software (HIPPOMIOT V R ). 23 The software provided the T2* value for all the 16 segments of the left ventricle (LV). Global heart T2* value was obtained by averaging all segmental values. Hepatic T2* values were calculated in a circular region of interest 24 and were converted into liver iron concentration (LIC) using the Wood's calibration curve. 25, 26 For the quantification of biventricular function parameters, cine images were acquired in sequential 8 mm short-axis slices. Images were analysed using MASS V R software (Medis, Leiden, The Netherlands). Atrial areas were measured from the four chamber view projection in ventricular end-systolic phase.
To detect the presence of myocardial fibrosis, LGE short-axis images were acquired 10-18 min after Gadobutrol (Gadovist V R ; Bayer Schering Pharma; Berlin, Germany) intravenous administration at the standard dose of 0.2 mmoL/kg. Also, vertical, horizontal, and oblique long-axis views were acquired. LGE images were not acquired in patients with a glomerular filtration rate < 30 mL/min/1.73 m 2 and in patients who refused.
LGE was considered present when visualized in two different views. 9, 27 The extent of LGE areas was quantified using a validated software.
9,28
Diagnostic criteria HF was identified based on symptoms, signs, biomarkers and instrumental parameters, according to the AHA/ACC guidelines. 29 Arrhythmias were diagnosed and classified according to the AHA/ ACC Guidelines. 30 Pulmonary hypertension (PH) was diagnosed if the trans-tricuspidal velocity jet was >3.2 m/s, 31 in presence of signs and symptoms.
If a patient developed more than one complication, only the first one was taken into account.
The term 'cardiac complications' included HF, arrhythmias, and PH. A T2* measurement of 20 ms was taken as 'conservative' normal value for segmental and global values. 12, 15, 23 Four patterns of MIO were identified by the segmental approach: no MIO (all segments with T2*> _20 ms), heterogeneous MIO (some segments with T2* > _20 ms and other segments with T2* <20 ms) and global heart T2* > _20 ms, heterogeneous MIO and global heart T2* <20 ms, and homogeneous MIO (all T2*values <20 ms). Heart dysfunction was diagnosed in presence of LV and/or right ventricular (RV) ejection fraction (EF) <2 standard deviations (SD) from the mean values normalized to age and gender. 
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A MR LIC > _3 mg/g/dw was considered indicative of significant iron load. 34 Mean serum ferritin levels between 1000 and 2500 ng/mL were considered indicative of mild-moderate iron overload 12 while values > _ 2500 ng/mL indicated severe iron overload. 35 
Statistical analysis
All data were analysed using SPSS version 13.0 Continuous variables were described as mean ± SD. Categorical variables were expressed as frequencies and percentages.
The Cox proportional-hazard model was used to test the association between the considered prognostic variables and the outcomes. All the continuous prognostic variables were made discrete by grouping patients into subcategories. All CMR variables showing an association with P < 0.10 at the univariate model were placed in the multivariate model and were ruled out only if they did not significantly improve the adjustment of the model. The results were presented as hazard ratio (HR) with 95% confidence intervals (CI).
Kaplan-Meier curves were generated by relating the development of an outcome over time to each significant prognosticator. The log rank test was used to compare different strata in Kaplan-Meier analyses.
A P < 0.05 was considered statistically significant.
Results

Baseline data
Fifty-six patients were excluded because a cardiac complication (26 arrhythmias, 21 HF, and 9 PH) was present at the baseline MR. Data of the 481 white TM patients considered are shown in Table 1 .
Liver iron overload was not assessed in two patients and cine images were not acquired in eight patients due to lack of collaboration. Bi-atrial areas were present for 414 patients due to technical reasons.
The contrast medium was not administrated in 49(10.2%) patients. No patients showed an ischemic pattern. Among the patients with LGE, the 57.7% had two or more foci of fibrosis. Of the 156 areas of fibrosis, 115(73.7%) involved the septum. Figure 1 shows a LGE short axis image of a patient with fibrosis.
Summary of primary end-points
Mean follow-up time was 57.91 ± 18.23 months (median = 55.21 months).
Cardiac events were recorded in 36 patients (1.6%/year): 18 episodes of HF, 16 arrhythmias, and 2 PH. Due to the low number of cases, no analysis was produced for PH.
Mean age at the first complication was 35.0 ± 7.76 years (range: 17-47 years).
Mean time from the first MR to the development of a cardiac complication was 22.31 ± 18.38 months and 15(41.7%) cardiac events occurred within the first year of follow-up.
Heart failure
Mean time of onset from the time of the MR scan to an episode of HF was 24.81 ± 18.14 months (range: 1-67 months). Thirteen (72.2%) episodes were recorded within 3 years. Mean age at the appearance of the HF was 32.11 ± 8.86 years.
Fifteen patients presented to the healthcare provider with a reduction in their effort tolerance due to dyspnoea and/or fatigue. Out of them, three were hospitalized. All the hospitalized patients had shown at the baseline CMR ventricular dysfunction and cardiac iron (two with an homogeneous pattern of MIO and one with an heterogeneous pattern of MIO and a global heart T2*value <20 ms). Three patients presented with symptoms of another cardiac disorder. 27 .61 ± 12.27 ms) but no significantly (P = 0.072).
Among the non-CMR parameters, the DM was a significant univariate prognosticator of HF.
Among the CMR parameters, heart iron, ventricular dysfunction, and myocardial fibrosis were identified as univariate prognosticators ( Table 2) . In the multivariate analysis the independent predictive factors were myocardial fibrosis (HR = 10.94, 95% CI = 3.28-36.43, P < 0.0001), homogeneous MIO (compared with no MIO) (HR = 5.56, 95% CI = 1.37-22.51, P = 0.016), and ventricular dysfunction (HR = 4.33, 95% CI = 1.39-13.43, P = 0.011) (Figure 2A) . Kaplan-Meier curves showing the impact of each predictive factor on the development of HF are shown in Figure 2B . The log-rank test revealed a significant difference in the curves for each predictor (fibrosis: P < 0.0001, MIO pattern: P = 0.016, ventricular dysfunction: P < 0.0001).
The extent of myocardial fibrosis was comparable in patients who developed HF and who did not (1.96 ± 1.18 vs. 1 .92 ± 1.47%; P = 0.681).
Arrhythmias
All 16 patients had supraventicular arrhythmias. Mean time from the MR to an episode of arrhythmia was 20.32 ± 19.52 months (range: 1-60 months). Mean age at the appearance of the first arrhythmia was 37.41 ± 5.01 years.
Baseline global heart T2* was comparable between patients who developed arrhythmias and those who remained free of arrhythmias (25.69 ± 12.81 vs. 27 .43 ± 12.44 ms; P = 0.604).
Older age, HCV-RNA positivity, and DM were identified as univariate prognosticators, while among the CMR parameters only atrial dilation was a prognosticator ( Table 3 and Figure 3A) . The KaplanMeier curve is shown in Figure 3B . The log-rank test revealed a significant difference (P = 0.002).
Cardiac complications
Patients who developed a cardiac complication had a significant lower baseline global heart T2* than patients free of events (22.98 ± 14.09 vs. 27 .72 ± 12.25 ms; P = 0.049). 
Male gender, HCV-RNA positivity, and DM were identified as non-CMR univariate prognosticators while, among the CMR parameters cardiac iron, ventricular dysfunction, myocardial fibrosis, and atrial dilation were identified as univariate prognosticators ( Table 4) .
In the multivariate analysis the independent predictive factors were myocardial fibrosis (HR = 4.94, 95% CI = 2.42-10.9, P < 0.0001), homogeneous pattern of MIO (compared with no MIO) (HR = 2.71, 95% CI = 1.12-6.59, P = 0.028), ventricular dysfunction (HR = 2.70, 95% CI = 1.29-5.63, P = 0.008) ( Figure 4A) . Figure 4B shows the Kaplan-Meier curves. The log-rank test revealed a significant difference in the curves for each predictor (myocardial fibrosis: P < 0.0001, MIO pattern: P = 0.026, ventricular dysfunction:
The extent of myocardial fibrosis was comparable in patients with and without cardiac complications (1.42 ± 1.05 vs. 2 .04 ± 1.50%; P = 0. 
Effect of prior history of cardiac complications
Thirty patients had a prior and resolved history of cardiac disease (10 HF, 16 supraventricular arrhythmias, 2 HF and supraventricular arrhythmias, and 2 ventricular arrhythmias). Out of the 18 patients who developed HF during the follow-up, only two (11.1%) had a prior history of HF. The HR for previous HF predicting future HF was 5.25 Out of the 16 patients who developed supraventricular arrhythmias, 8(50%) had a prior history of supraventricular arrhythmias. The HR for previous predicting future supraventricular arrhythmias was 37. 66 (95% CI = 14.04-100.99, P < 0.0001). When the previous supraventricular arrhythmias were included in the multivariate model, they remained the only independent predictor.
Out of the 36 patients who developed cardiac complications, 13(36.1%) had a prior history of cardiac complications. The HR for previous cardiac complications predicting future cardiac complications was 11 .49(95% CI = 5.78-22.88; P < 0.0001). When the previous cardiac complications were included in the multivariate model, the independent predictive factors were: myocardial fibrosis (HR = 6.33, 95% CI = 3.04-13.22, P < 0.0001), homogeneous MIO (HR = 3.07, 95% CI = 1.26-7.47, P = 0.013), and previous cardiac complications (HR = 19.00, 95% CI = 8.84-40.82, P < 0.0001).
Chelation therapy
Among the patients who changed the chelation regimen during the follow-up (69.6%), 26 .2% underwent dose modification while 73.8% switched to a different type of chelator.
Patients who changed chelation regimen were more likely to have a global heart T2* value <20 ms (38.4 vs. 25 .0%; P = 0.007) and to have a baseline LIC > _ 3 mg/g/dw (76.7 vs. 63.6%; P = 0.005).
Discussion
All our patients underwent the MR examination assessing multiparametric findings (heart and liver iron, myocardial fibrosis, atrial areas, and biventricular function parameters). 7, 9, 14 The incidence of HF and arrhythmias in our study were 0.8 and 0.7% per year, respectively, significantly lower than the clinical experience reported by the Royal Brompton between 1999 and 2006 (6.2 and 7.7% per year). 2 Several reasons might explain the difference.
First of all, the strong predictive value of cardiac T2* was not generally accepted among haematologists in the early 2000s, leading to inadequate escalation of chelation therapy in response to cardiac iron detection. Secondly, we followed a homogeneous white Italian population well-treated since early childhood. Moreover, we started the follow-up 5 years later, putting our population in a different chelation era. In fact, in comparison to the study of Kirk, 2 the percentages of patients under Desferrioxamine were about half and under Deferiprone about double. Moreover, Deferasirox had been introduced in clinical arena. The combination of improved chelation compliance with oral iron chelators, 16, 36, 37 improved rescue therapies, 37 wider use of Deferiprone, 16, 38 and early, aggressive response to the presence of MIO may all contribute to the better outcomes. 16, 38 In our homogenous cohort of well-treated patients, traditional markers of iron loading for the prediction of cardiac complications, such as LIC and serum ferritin, have lost their power in predicting cardiac complications. More specific and direct parameters are needed. Cardiac T2* can identify preclinical cardiac iron deposition in patients with excellent control of total body iron stores. 16, 19, 38, 39 However, cardiac T2* was less strongly associated with cardiac complications than previously described because abnormal T2* prompted changes in clinical management. As a result, also other CMR parameters such as LGE and ventricular dysfunction emerged as important predictors of cardiac complications. These data demonstrated the importance of multi-parametric CMR studies in thalassemia patients. With improved control of MIO, myocardial fibrosis emerges as the strongest predictor for HF and cardiac complications. Although myocardial fibrosis is known to have prognostic implications in other cardiomyopathies, 40 its clinical implications in TM have not been well-studied. Historical post-mortem studies demonstrated significant cardiac fibrosis 41, 42 and myocardial 19 We hypothesize that also this low amount of fibrosis represents the sign of myocardial damage. Beyond CMR, DM, and previous cardiac complications were the strongest clinical predictors for HF and cardiac complications, consistent with observations in the general population. 44 In a previous retrospective historical TM cohort, DM was demonstrated to lead to an higher frequency of cardiac complications, 10 but not prospective data were available. Our findings suggest the importance of diagnosing and correcting glucose dysregulation as well as the need for primary prevention by the intensification of the chelation therapy in patients in whom excess pancreatic iron is found by MR. 45 CMR was less helpful in predicting cardiac arrhythmias, with only atrial dilatation emerging as risk factor. However, even this risk factor disappeared when prior history of arrhythmia was incorporated into the model, suggesting less reversibility than derangements of cardiac MIO contributes less to the development of supraventricular arrhythmias than to cardiac failure. The incidence of arrhythmias was nearly 11-fold lower than previous reports, suggesting that improved ironchelation strongly modifies arrhythmia risk. The atrial myocardium might be more sensitive to iron deposition than the ventricle in the causation of arrhythmias. Unfortunately, T2* measurements of the thin atria are not robust. Beyond the CMR, age older than 40 years was a predictor for arrhythmias. TM patients are also susceptible to noniron-dependent causation of atrial arrhythmia because of the longstanding proarrhythmic atrial effects of high cardiac output. HCV-RNA Prediction of cardiac complications for thalassemia major positivity and DM were significant prognosticators in the univariate analysis ( Table 2) , partially confirming the results found in a previous large retrospective historical TM cohort. 10 
Conclusion
Cardiac complications in well-chelated and well-monitored TM patients are significantly rarer than previously reported, since the entire strategy around cardiac iron assessment, monitoring, and therapy has been completely changed by the use of myocardial T2*. Myocardial fibrosis, severe and homogeneous MIO and ventricular dysfunction are predictive for the development of HF and cardiac complications. In contrast, traditional markers of cardiac risk such as LIC and serum ferritin have lost their predictive power. The only significant prognosticator of arrhythmias was atrial dilatation. So, a widespread program using MR exploiting its multi-parametric potential can have considerable power for opening the prognosis of TM patients by the early identification and treatment of patients at risk for cardiac complications.
